Special purpose acquisition company Research Alliance Corporation III, initiated by the prominent healthcare investment firm RA Capital Management, announced on May 20 the pricing of its $75 million initial public offering, with its shares beginning trading on the Nasdaq Capital Market the same day.

**IPO Exceeds Expectations, Attracts Major Institutional Investors** The offering consisted of 7.5 million Class A ordinary shares, priced at $10.00 per share, generating total gross proceeds of $75 million. Notably, the company initially filed with the SEC in March with plans to raise $50 million, before increasing the offering size by 50% to $75 million earlier this month. Unlike many SPACs, this offering included only ordinary shares and did not incorporate warrants or rights.

Leerink Partners acted as the sole book-running manager for the offering. The investor roster drew significant market attention, with participation from several institutions including ADAR1 Capital, Balyasny Asset Management, BVF Partners, Cormorant Asset Management, Janus Henderson Investors, and Perceptive Advisors.

**Focus on Healthcare Industry Mergers and Acquisitions** Research Alliance Corporation III was incorporated in the Cayman Islands on February 19, 2026, as a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, or similar business combination. The company is led by Dr. Matthew Hammond, a partner at RA Capital Management, as Chief Executive Officer, and Henry Stusnick as Chief Business Officer and Chief Operating Officer.

While the company may pursue a target in any business or industry and in any geographic region, management has explicitly stated a primary focus on the healthcare or healthcare-related industries, particularly companies in drug discovery and commercialization, diagnostics, and medical technology and services. According to prior SEC filings, the company does not rule out seeking a target among companies in which RA Capital holds an investment and may pursue a transaction where the pre-combination shareholders hold a minority stake post-merger.

**Extensive Prior SPAC Operational Experience** RA Capital has an established track record in the SPAC space. Its first SPAC, Research Alliance I, merged with POINT Biopharma, which was subsequently acquired by Eli Lilly in 2023. Its second SPAC, Research Alliance II, completed an IPO in 2021 but was later liquidated.

The company has also noted in previous filings that while the current window for biotech IPOs is largely closed, this environment may enhance its ability to "find attractive targets." Furthermore, the company expressed optimism regarding the significant volume of drug licensing deal opportunities emerging in the Chinese biotech sector and may seek merger targets in that region.

The offering is expected to close on May 21, with the underwriter granted a 45-day option to purchase additional shares.